Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer
Tatjana Bilich(Stanford University), Juliane S. Walz(University Children's Hospital Tübingen)
Cited by 47
Related Papers
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma
|Nature Communications|2022|73